BiotechTube
EicOsis

EicOsis

Davis, United States· Est.
eicosis.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $14.5M

Overview

EicOsis, founded in 2015 and based in Davis, California, is pioneering a new class of oral analgesics and anti-inflammatories by inhibiting the soluble Epoxide Hydrolase (sEH) enzyme. This mechanism increases endogenous fatty acid mediators to treat pain without the addictive potential of opioids. The company's lead program, EC5026, is in Phase 1 clinical development, with a specific trial for neuropathic pain from spinal cord injury funded by the Department of Defense. EicOsis represents a promising private venture targeting the massive unmet need in chronic pain treatment.

Chronic PainNeuropathic PainInflammation

Technology Platform

Small molecule inhibitors of the soluble Epoxide Hydrolase (sEH) enzyme, which increase endogenous levels of anti-inflammatory and analgesic fatty acid epoxides.

Funding History

3
Total raised:$14.5M
Grant$2M
Series A$10M
Seed$2.5M

Opportunities

The urgent, large-scale need for non-addictive pain medications driven by the opioid crisis creates a receptive market and regulatory environment.
The sEH platform also shows preclinical promise for expansion into major central nervous system disorders like Alzheimer's disease and traumatic brain injury, offering significant long-term potential.

Risk Factors

The lead compound faces the high risk of clinical failure common to all drug development, particularly in proving efficacy in patient trials.
The company is also a pre-revenue, private entity dependent on successful fundraising and milestone achievement to continue operations.

Competitive Landscape

EicOsis competes in the crowded but high-need pain therapeutics space, facing established NSAIDs and opioids, as well as newer non-opioid modalities in development from large pharma and biotech (e.g., NGF inhibitors, NaV channel blockers). Its differentiation hinges on the novel sEH mechanism offering a potentially safer, oral, and non-addictive profile.

More companies in Small Molecule Drugs →More companies in United States →